Table 2.
Characteristics of study subjects at baseline, 3, and 6 month visits.
| Baseline | 3 months | 6 months | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Blephasteam (n = 37) | TheraPearl (n = 33) | P-valuea | Blephasteam (n = 34) | TheraPearl (n = 28) | P-valueb | Blephasteam (n = 25) | TheraPearl (n = 23) | P-valuec | |
| Mean age | 52.2 (46.8, 57.6) | 55.1 (49.1, 61.2) | 0.46 | 53.4 (47.8, 59.1) | 57.1 (50.8, 63.5) | 0.38 | 52.8 (46.4, 59.2) | 58.0 (51.4, 54.6) | 0.25 |
| Sex (female) | 70.3% | 69.7% | 0.96 | 69.7% | 67.9% | 0.88 | 62.5% | 77.3% | 0.28 |
| OSDI |
38.7 (31.9, 45.5) |
32.9 (26.1, 39.7) | 0.23 | 24.5 (17.1, 31.8) | 22.0 (14.2, 29.8) | 0.64 | 23.2 (14.3, 32.2) | 21.2 (14.8, 27.6) | 0.70 |
| FBUT (s) | 4.7 (4.0, 5.4) | 4.9 (4.0, 5.8) | 0.74 | 7.2 (5.9, 8.4) | 7.3 (5.5, 9.1) | 0.88 | 8.5 (6.6, 10.3) | 6.8 (5.2, 8.4) | 0.16 |
| OSS† | 1.50 (1.00, 1.50) | 1.00 (1.00, 1.01) | 0.58 | 1.50 (1.49, 2.00) | 1.00 (1.00, 1.00) | < 0.01 | 1.50 (1.00, 2.50) | 2.00 (1.50, 2.50) | 0.17 |
| Schirmer’s test (mm/5 min) | 17.7 (14.2, 21.2) | 18.9 (14.9, 22.9) | 0.66 | 17.8 (14.0, 21.8) | 17.4 (13.2, 21.5) | 0.86 | 22.3 (17.2, 27.5) | 17.1 (13.0, 21.2) | 0.11 |
| MQ† | 7.00 (6.50, 8.00) | 6.50 (5.50, 7.50) | 0.76 | 5.5 (4.5, 6.0) | 5.5 (5.0, 6.5) | 0.53 | 5.50 (4.50, 6.50) | 5.00 (4.50, 6.00) | 0.40 |
| ME† | 2.00 (2.00, 2.50) | 2.00 (1.50, 2.00) | 0.84 | 1.50 (1.49, 1.50) | 1.50 (1.00, 1.50) | 0.81 | 1.00 (1.00, 1.50) | 1.50 (1.00, 2.00) | 0.34 |
Values are displayed as means with a 95% confidence interval.
†Median values were reported.
ap-value between the two groups at baseline.
bAt 3 months.
cAt 6 months. P-values given in bold are considered statistically significant.
OSDI ocular surface disease index measured on a scale from 0 to 100, FBUT fluorescein breakup time, OSS ocular surface staining scored with the Oxford grading scheme from 0 to 1542, MQ meibomian quality scored on a scale from 0 to 24, ME meibomian expressibility scored on a scale from 0 to 3.